long-term adjuv therapi high-risk malign melanoma interferon alpha fifty-thre high-risk melanoma patient stage patient stage II standard surgic intervent adjuv therapi recombin interferon rifn therapi total period month concomit patient stage stage II ident stage prognost factor adjuv therapi efficaci rifn alpha therapi differ relaps incid overal surviv rate patient stage II benefit long-term adjuv rifn therapi treatment period month incid relaps comparison control treatment incid relaps equal treat control group result studi continu low-dos rifn therapi adjuv treatment malign melanoma 